GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Brooks Laboratories Ltd

Brooks Laboratories Q2 FY27: Net Profit Rs. 6,998.82 Lakhs (Standalone)

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 07 Nov 2026, 06:06 PM IST  ·  BSE ID: 191d25ee-2f69-404f-8b47-3fcf507f41a1
View Original BSE Filing (PDF)
💡
In Simple Terms
Brooks Laboratories reported its latest quarterly results, with a significant profit boost from selling part of an investment.
🤖 AI Summary
  • Board approved unaudited standalone and consolidated financial results for Q2 FY27 and half year ended September 30, 2026.
  • Standalone Net Profit for Q2 FY27 was Rs. 6,998.82 Lakhs, including an exceptional gain of Rs. 7,470.00 Lakhs.
  • The exceptional gain resulted from partial divestment of 11.48% stake in Brooks Steriscience Limited for Rs. 7,473.60 Lakhs.
  • Consolidated Net Profit for Q2 FY27 stood at Rs. 6,761.00 Lakhs, also reflecting the exceptional item.
  • Standalone Revenue from operations for Q2 FY27 was Rs. 1,924.79 Lakhs, compared to Rs. 2,345.07 Lakhs in Q2 FY26.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from operations Q2 FY27
1,924.79 Rs. In Lakhs
Standalone Revenue from operations Q2 FY26
2,345.07 Rs. In Lakhs
Standalone Net Profit after tax Q2 FY27
6,998.82 Rs. In Lakhs
Standalone Net Profit after tax Q2 FY26
223.73 Rs. In Lakhs
Exceptional items income Q2 FY27
7,470.00 Rs. In Lakhs
Consolidated Net Profit after tax Q2 FY27
6,761.00 Rs. In Lakhs
Consolidated Net Profit after tax Q2 FY26
797.69 Rs. In Lakhs
Basic EPS (Standalone) Q2 FY27
23.76 Rs. per share
Basic EPS (Standalone) Q2 FY26
0.76 Rs. per share
🏢 How This Affects the Company
📈
Business Impact
The partial divestment in Brooks Steriscience Limited indicates a strategic re-evaluation of its investment portfolio, shifting equity stake from 49.00% to 37.52%.
💰
Financial Impact
Net profit for Q2 FY27 was significantly impacted by an exceptional gain of Rs. 7,470.00 Lakhs from the divestment, rather than core operational income.
⚙️
Operational Impact
The reduction in shareholding in Brooks Steriscience Limited means the company continues to exercise significant influence, rather than control, over its activities.
⚠️
Risk Impact
No deferred tax asset was recognized on business losses/depreciation, indicating management's view on the absence of reasonable certainty for future taxable profit, as per Ind AS 12.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported Q2 FY27 Standalone Net Profit of Rs. 6,998.82 Lakhs and the impact of the exceptional item.
🔍
Management Signal
The management's decision to partially divest an equity stake signals a strategic capital allocation move, focusing on realizing gains from investments.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — evaluate core operational revenue growth excluding exceptional items.
Updates on Brooks Steriscience Limited performance — assess impact of associate losses.
Further details on capital allocation strategy after the partial divestment.
MEDIUM RISK Reliance on exceptional gains for profitability and decline in core operational revenue are concerns.
💡 Investor Takeaway
Brooks Laboratories reported a Standalone Net Profit of Rs. 6,998.82 Lakhs for Q2 FY27, largely driven by an exceptional gain of Rs. 7,470.00 Lakhs from divesting a partial stake in Brooks Steriscience Limited. Standalone Revenue from operations for Q2 FY27 was Rs. 1,924.79 Lakhs, lower than prior year.
⚖️ Strengths & Concerns

✅ Positives

  • Exceptional gain of Rs. 7,470.00 Lakhs from partial divestment in Brooks Steriscience Limited positively impacted Q2 FY27 net profit.
  • Company continues to hold 37.52% equity stake in Brooks Steriscience Limited, retaining significant influence despite divestment.

⚠️ Concerns

  • Standalone Revenue from operations decreased to Rs. 1,924.79 Lakhs in Q2 FY27 from Rs. 2,345.07 Lakhs in Q2 FY26.
  • Company's share of loss after tax from jointly controlled entity Brooks Steriscience Limited was Rs. 558.37 Lakhs for the half year ended September 30, 2026.
❓ Frequently Asked Questions
What was Brooks Laboratories' Standalone Net Profit for Q2 FY27?
Brooks Laboratories reported a Standalone Net Profit after tax of Rs. 6,998.82 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What contributed to the exceptional item in Q2 FY27 results?
The exceptional item income of Rs. 7,470.00 Lakhs resulted from the partial divestment of an 11.48% equity stake in Brooks Steriscience Limited for an aggregate consideration of Rs. 7,473.60 Lakhs.
What was the Standalone Revenue from operations for Brooks Laboratories in Q2 FY27?
The Standalone Revenue from operations for Brooks Laboratories was Rs. 1,924.79 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
How much stake does Brooks Laboratories still hold in Brooks Steriscience Limited?
Following the partial divestment, Brooks Laboratories continues to hold a 37.52% equity stake in Brooks Steriscience Limited.
What was the Consolidated Net Profit for Brooks Laboratories in Q2 FY27?
Brooks Laboratories reported a Consolidated Net Profit after tax of Rs. 6,761.00 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.